THE EFFECT OF BREED ON REPRODUCTIVE PERFORMANCE IN COMMODITY RABBIT PRODUCTION

The aim of this study was to assess the reproductive rates among different breeds, mostly used in commodity farm conditions. The studies were obtained at fertility level from 6.27 animals in the Californian breed to 8.49 animals in Popielno White. High rate of failures during rearing was observed in the Californian breed. Litter weight was dependent on the number of births and young rearing, lactation and care of female. Kitten weight at 35 day of age ranged from 603.21g (Alaskan) to 736.10g (Giant Chinchilla). The results indicate the usefulness of a Popielno White breed for the livestock production

Statistical Analysis of Conformation Traits of New Zealand White Rabbits in a Breeding Farm

The aim of the study was the statistical analysis of conformation traits ofNew Zealandwhite rabbits from a breeding farm for a period of ten years. Analysis of variance showed a statistically highly significant effect of gender on body size and weight of the animal, as well as on fur quality, body built and racial type. The year of license had statistically highly significant impact on animal size, body weight, fur quality, the specific racial features, body built, racial type and the total number of points received by the rabbits. The interaction of gender and year of license had statistically high impact only on body weight, while there was no statistically significant effect for other analyzed traits. The study also estimated phenotypic correlations between the studied traits. The correlations were quite varied and ranged between - 0.772 (between racial type and the year of the license) to 0.6017 (between body built and the total sum of points).

Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry

Aims: This study aimed to assess age- and sex-related differences in management and 1-year risk for all-cause mortality and hospitalization in chronic heart failure (HF) patients. Methods and results: Of 16 354 patients included in the European Society of Cardiology Heart Failure Long-Term Registry, 9428 chronic HF patients were analysed [median age: 66 years; 28.5% women; mean left ventricular ejection fraction (LVEF) 37%]. Rates of use of guideline-directed medical therapy (GDMT) were high (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers and mineralocorticoid receptor antagonists: 85.7%, 88.7% and 58.8%, respectively). Crude GDMT utilization rates were lower in women than in men (all differences: P\ua0 64 0.001), and GDMT use became lower with ageing in both sexes, at baseline and at 1-year follow-up. Sex was not an independent predictor of GDMT prescription; however, age >75 years was a significant predictor of GDMT underutilization. Rates of all-cause mortality were lower in women than in men (7.1% vs. 8.7%; P\ua0=\ua00.015), as were rates of all-cause hospitalization (21.9% vs. 27.3%; P\ua075 years. Conclusions: There was a decline in GDMT use with advanced age in both sexes. Sex was not an independent predictor of GDMT or adverse outcomes. However, age >75 years independently predicted lower GDMT use and higher all-cause mortality in patients with LVEF 6445%

THE EFFECT OF BREED ON REPRODUCTIVE PERFORMANCE IN COMMODITY RABBIT PRODUCTION

The aim of this study was to assess the reproductive rates among different breeds, mostly used in commodity farm conditions. The studies were obtained at fertility level from 6.27 animals in the Californian breed to 8.49 animals in Popielno White. High rate of failures during rearing was observed in the Californian breed. Litter weight was dependent on the number of births and young rearing, lactation and care of female. Kitten weight at 35 day of age ranged from 603.21g (Alaskan) to 736.10g (Giant Chinchilla). The results indicate the usefulness of a Popielno White breed for the livestock production

Chorzy z implantowanym urządzeniem do elektroterapii serca poddawani radioterapii w warunkach polskich

Starszy wiek oraz wysoka chorobowość społeczeństwa powodują, że rosnąca liczba pacjentów z urządzeniem do elektroterapii serca (CIED) wymaga skutecznego leczenia nowotworów, w tym radioterapii (RT). Wpływ RT na CIED może się różnić w zależności od rodzaju i parametrów fizycznych promieniowania, umiejscowienia leczonej zmiany, wskazań do elektroterapii i rodzaju CIED. W najbardziej dramatycznych scenariuszach może powodować nieodwracalne uszkodzenie CIED z poważnymi konsekwencjami klinicznymi. Brak dokładnych wytycznych może skutkować niepotrzebną dyskwalifikacją z RT lub terapią bez zachowania koniecznych środków ostrożności, co może pogorszyć rokowanie. Dlatego jasne i jednoznaczne zalecenia dotyczące kwalifikacji do RT mają pozwolić na podjęcie odpowiednich środków ostrożności oraz umożliwić pacjentom ze współistniejącymi chorobami kardiologicznymi i onkologicznymi bezpieczną i efektywną RT.Starszy wiek oraz wysoka chorobowość społeczeństwa powodują, że rosnąca liczba pacjentów z urządzeniem do elektroterapii serca (CIED) wymaga skutecznego leczenia nowotworów, w tym radioterapii (RT). Wpływ RT na CIED może się różnić w zależności od rodzaju i parametrów fizycznych promieniowania, umiejscowienia leczonej zmiany, wskazań do elektroterapii i rodzaju CIED. W najbardziej dramatycznych scenariuszach może powodować nieodwracalne uszkodzenie CIED z poważnymi konsekwencjami klinicznymi. Brak dokładnych wytycznych może skutkować niepotrzebną dyskwalifikacją z RT lub terapią bez zachowania koniecznych środków ostrożności, co może pogorszyć rokowanie. Dlatego jasne i jednoznaczne zalecenia dotyczące kwalifikacji do RT mają pozwolić na podjęcie odpowiednich środków ostrożności oraz umożliwić pacjentom ze współistniejącymi chorobami kardiologicznymi i onkologicznymi bezpieczną i efektywną RT

Patients with cardiac implantable electronic devices undergoing radiotherapy in Poland. Expert opinion of the Heart Rhythm Section of the Polish Cardiac Society and the Polish Society of Radiation Oncology

ABSTRACT Older age and high morbidity of the society contribute to a growing number of patients with cardiac implantable electronic devices (CIEDs) requiring effective cancer treatment, including radiotherapy (RT). The effect of RT on a CIED may vary depending on the type and physical parameters of radiation, location of the treated lesion, indications for electrotherapy, and the type of CIED. In the most dramatic scenarios, it may cause an irreversible damage to the CIED, with serious clinical consequences. The lack of precise guidelines may limit the access to RT for many patients with CIEDs who would otherwise benefit from the therapy or may lead to a therapy without taking the necessary precautions, which may worsen the prognosis. Therefore, clear and unequivocal recommendations for assessing patient eligibility for RT are aimed at ensuring that adequate precautions are taken as well as at providing patients with concomitant cardiovascular and oncologic diseases with access to safe and effective RT

Radiation therapy in patients with cardiac implantable electronic devices

Background: The number of patients with cardiac implantable electronic devices (CIEDs) treated with radiation therapy (RT) as an oncological treatment is expected to increase. Aims: The aim of the study was to assess whether cancer treatment with radiation therapy is associated with any device dysfunctions and device‑related threats in patients with CIEDs. Methods: The risk of all patients with CIEDs undergoing RT was assessed according to guidelines. Device interrogations were performed before the first and after the last RT session. In patients at high risk and/or with an implantable cardioverter‑defibrillator or cardiac resynchronization therapy with defibrillator (CRT‑D), all sessions were supervised by a cardiologist, and device interrogations were performed before and after every single RT session. Device parameters and events were monitored during thewhole treatment. Results: The study included 157 patients with CIEDs who had palliative (n = 71) or radical (n = 86) RT. Pacemakers were implanted in 113 patients, implantable cardioverter‑defibrillators in 36, and CRT‑D in 8. During the 2396 RT sessions (median [interquartile range], 5 [5–28] per patient) with cumulative dose up to 78 Gy per patient for the whole RT treatment and maximum energy beam up to 20 MV, 2 events potentially related to radiation were recorded. Conclusions: Radiation therapy in patients with CIEDs is not associated with substantial risk to the patients assuming the patients’ management follows current guidelines.

Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

Aims: To assess the proportion of patients with heart failure and reduced ejection fraction (HFrEF) who are eligible for sacubitril/valsartan (LCZ696) based on the European Medicines Agency/Food and Drug Administration (EMA/FDA) label, the PARADIGM-HF trial and the 2016 ESC guidelines, and the association between eligibility and outcomes. Methods and results: Outpatients with HFrEF in the ESC-EORP-HFA Long-Term Heart Failure (HF-LT) Registry between March 2011 and November 2013 were considered. Criteria for LCZ696 based on EMA/FDA label, PARADIGM-HF and ESC guidelines were applied. Of 5443 patients, 2197 and 2373 had complete information for trial and guideline eligibility assessment, and 84%, 12% and 12% met EMA/FDA label, PARADIGM-HF and guideline criteria, respectively. Absent PARADIGM-HF criteria were low natriuretic peptides (21%), hyperkalemia (4%), hypotension (7%) and sub-optimal pharmacotherapy (74%); absent Guidelines criteria were LVEF>35% (23%), insufficient NP levels (30%). and sub-optimal pharmacotherapy (82%); absent label criteria were absence of symptoms (New York Heart Association class I). When a daily requirement of ACEi/ARB ≥ 10 mg enalapril (instead of ≥ 20 mg) was used, eligibility rose from 12% to 28% based on both PARADIGM-HF and guidelines. One-year heart failure hospitalization was higher (12% and 17% vs. 12%) and all-cause mortality lower (5.3% and 6.5% vs. 7.7%) in registry eligible patients compared to the enalapril arm of PARADIGM-HF. Conclusions: Among outpatients with HFrEF in the ESC-EORP-HFA HF-LT Registry, 84% met label criteria, while only 12% and 28% met PARADIGM-HF and guideline criteria for LCZ696 if requiring ≥ 20 mg and ≥ 10 mg enalapril, respectively. Registry patients eligible for LCZ696 had greater heart failure hospitalization but lower mortality rates than the PARADIGM-HF enalapril group